Quality Circle: Profitability, Integrity and the Cost of Poor Quality

Bikash Chatterjee, President & CSO

As major blockbuster drugs come off patent, the scramble among generics to capture these new markets is just beginning. We can expect the U.S. market to experience continued change and consolidation with cost cutting remaining at the top of the priority list for big pharma.